[18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer

Francesco Pasqualetti, Marco Panichi, Martina Sollini, Aldo Sainato, Luca Galli, Riccardo Morganti, Serena Chiacchio, Andrea Marciano, Roberta Zanca, Lorenzo Mannelli, Gabriele Coraggio, Andrea Sbrana, Paola Cocuzza, Sabrina Montrone, Davide Baldaccini, Alessandra Gonnelli, Alessandro Molinari, Martina Cantarella, Valentina Mazzotti, Sergio RicciFabiola Paiar, Paola Anna Erba

Research output: Contribution to journalArticle

Abstract

Background: In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [18F]Fluoro-Methyl Choline ([18F]FMCH) PET/CT in the selection of PCa patients suitable for stereotactic body radiotherapy (SBRT). Methods: Patients with biochemical recurrence limited up to three lesions revealed by [18F]FMCH PET/CT were enrolled in the present study and treated with SBRT on all active lesions. Systemic therapy-free survival since the [18F]FMCH PET/CT was considered as the primary endpoint. Results: Forty-six patients were evaluated, and a total of 67 lesions were treated. After a median follow-up of 28.9 months, systemic therapy was started in 30 patients (65.2%) and median systemic therapy-free survival was 39.1 months (95% CI 6.5–68.6); 6, 12, and 24-month ratios were 93.5%, 73.9%, and 63.1%, respectively. At univariate Cox regression analysis, Delta PSA demonstrated an impact on systemic therapy-free survival (p < 0.001). Conclusions: Based on our findings, [18F]FMCH PET/CT can identify oligometastatic prostate cancer patients suitable for SBRT, resulting in a systemic therapy-free survival of 39.1 months.

Original languageEnglish
Pages (from-to)185-191
Number of pages7
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume47
Issue number1
DOIs
Publication statusPublished - Jan 1 2020

Fingerprint

Radiosurgery
Prostatic Neoplasms
Survival
Therapeutics
Choline
Regression Analysis
fluorocholine
Prospective Studies
Recurrence

Keywords

  • Prostate cancer
  • Stereotactic body radiotherapy
  • [F]FMCH PET/CT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

[18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer. / Pasqualetti, Francesco; Panichi, Marco; Sollini, Martina; Sainato, Aldo; Galli, Luca; Morganti, Riccardo; Chiacchio, Serena; Marciano, Andrea; Zanca, Roberta; Mannelli, Lorenzo; Coraggio, Gabriele; Sbrana, Andrea; Cocuzza, Paola; Montrone, Sabrina; Baldaccini, Davide; Gonnelli, Alessandra; Molinari, Alessandro; Cantarella, Martina; Mazzotti, Valentina; Ricci, Sergio; Paiar, Fabiola; Erba, Paola Anna.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 47, No. 1, 01.01.2020, p. 185-191.

Research output: Contribution to journalArticle

Pasqualetti, F, Panichi, M, Sollini, M, Sainato, A, Galli, L, Morganti, R, Chiacchio, S, Marciano, A, Zanca, R, Mannelli, L, Coraggio, G, Sbrana, A, Cocuzza, P, Montrone, S, Baldaccini, D, Gonnelli, A, Molinari, A, Cantarella, M, Mazzotti, V, Ricci, S, Paiar, F & Erba, PA 2020, '[18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer', European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. 1, pp. 185-191. https://doi.org/10.1007/s00259-019-04482-6
Pasqualetti, Francesco ; Panichi, Marco ; Sollini, Martina ; Sainato, Aldo ; Galli, Luca ; Morganti, Riccardo ; Chiacchio, Serena ; Marciano, Andrea ; Zanca, Roberta ; Mannelli, Lorenzo ; Coraggio, Gabriele ; Sbrana, Andrea ; Cocuzza, Paola ; Montrone, Sabrina ; Baldaccini, Davide ; Gonnelli, Alessandra ; Molinari, Alessandro ; Cantarella, Martina ; Mazzotti, Valentina ; Ricci, Sergio ; Paiar, Fabiola ; Erba, Paola Anna. / [18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer. In: European Journal of Nuclear Medicine and Molecular Imaging. 2020 ; Vol. 47, No. 1. pp. 185-191.
@article{123538e910264696a266ad7d6619dda0,
title = "[18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer",
abstract = "Background: In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [18F]Fluoro-Methyl Choline ([18F]FMCH) PET/CT in the selection of PCa patients suitable for stereotactic body radiotherapy (SBRT). Methods: Patients with biochemical recurrence limited up to three lesions revealed by [18F]FMCH PET/CT were enrolled in the present study and treated with SBRT on all active lesions. Systemic therapy-free survival since the [18F]FMCH PET/CT was considered as the primary endpoint. Results: Forty-six patients were evaluated, and a total of 67 lesions were treated. After a median follow-up of 28.9 months, systemic therapy was started in 30 patients (65.2{\%}) and median systemic therapy-free survival was 39.1 months (95{\%} CI 6.5–68.6); 6, 12, and 24-month ratios were 93.5{\%}, 73.9{\%}, and 63.1{\%}, respectively. At univariate Cox regression analysis, Delta PSA demonstrated an impact on systemic therapy-free survival (p < 0.001). Conclusions: Based on our findings, [18F]FMCH PET/CT can identify oligometastatic prostate cancer patients suitable for SBRT, resulting in a systemic therapy-free survival of 39.1 months.",
keywords = "Prostate cancer, Stereotactic body radiotherapy, [F]FMCH PET/CT",
author = "Francesco Pasqualetti and Marco Panichi and Martina Sollini and Aldo Sainato and Luca Galli and Riccardo Morganti and Serena Chiacchio and Andrea Marciano and Roberta Zanca and Lorenzo Mannelli and Gabriele Coraggio and Andrea Sbrana and Paola Cocuzza and Sabrina Montrone and Davide Baldaccini and Alessandra Gonnelli and Alessandro Molinari and Martina Cantarella and Valentina Mazzotti and Sergio Ricci and Fabiola Paiar and Erba, {Paola Anna}",
year = "2020",
month = "1",
day = "1",
doi = "10.1007/s00259-019-04482-6",
language = "English",
volume = "47",
pages = "185--191",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "1",

}

TY - JOUR

T1 - [18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer

AU - Pasqualetti, Francesco

AU - Panichi, Marco

AU - Sollini, Martina

AU - Sainato, Aldo

AU - Galli, Luca

AU - Morganti, Riccardo

AU - Chiacchio, Serena

AU - Marciano, Andrea

AU - Zanca, Roberta

AU - Mannelli, Lorenzo

AU - Coraggio, Gabriele

AU - Sbrana, Andrea

AU - Cocuzza, Paola

AU - Montrone, Sabrina

AU - Baldaccini, Davide

AU - Gonnelli, Alessandra

AU - Molinari, Alessandro

AU - Cantarella, Martina

AU - Mazzotti, Valentina

AU - Ricci, Sergio

AU - Paiar, Fabiola

AU - Erba, Paola Anna

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Background: In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [18F]Fluoro-Methyl Choline ([18F]FMCH) PET/CT in the selection of PCa patients suitable for stereotactic body radiotherapy (SBRT). Methods: Patients with biochemical recurrence limited up to three lesions revealed by [18F]FMCH PET/CT were enrolled in the present study and treated with SBRT on all active lesions. Systemic therapy-free survival since the [18F]FMCH PET/CT was considered as the primary endpoint. Results: Forty-six patients were evaluated, and a total of 67 lesions were treated. After a median follow-up of 28.9 months, systemic therapy was started in 30 patients (65.2%) and median systemic therapy-free survival was 39.1 months (95% CI 6.5–68.6); 6, 12, and 24-month ratios were 93.5%, 73.9%, and 63.1%, respectively. At univariate Cox regression analysis, Delta PSA demonstrated an impact on systemic therapy-free survival (p < 0.001). Conclusions: Based on our findings, [18F]FMCH PET/CT can identify oligometastatic prostate cancer patients suitable for SBRT, resulting in a systemic therapy-free survival of 39.1 months.

AB - Background: In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [18F]Fluoro-Methyl Choline ([18F]FMCH) PET/CT in the selection of PCa patients suitable for stereotactic body radiotherapy (SBRT). Methods: Patients with biochemical recurrence limited up to three lesions revealed by [18F]FMCH PET/CT were enrolled in the present study and treated with SBRT on all active lesions. Systemic therapy-free survival since the [18F]FMCH PET/CT was considered as the primary endpoint. Results: Forty-six patients were evaluated, and a total of 67 lesions were treated. After a median follow-up of 28.9 months, systemic therapy was started in 30 patients (65.2%) and median systemic therapy-free survival was 39.1 months (95% CI 6.5–68.6); 6, 12, and 24-month ratios were 93.5%, 73.9%, and 63.1%, respectively. At univariate Cox regression analysis, Delta PSA demonstrated an impact on systemic therapy-free survival (p < 0.001). Conclusions: Based on our findings, [18F]FMCH PET/CT can identify oligometastatic prostate cancer patients suitable for SBRT, resulting in a systemic therapy-free survival of 39.1 months.

KW - Prostate cancer

KW - Stereotactic body radiotherapy

KW - [F]FMCH PET/CT

UR - http://www.scopus.com/inward/record.url?scp=85074045009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074045009&partnerID=8YFLogxK

U2 - 10.1007/s00259-019-04482-6

DO - 10.1007/s00259-019-04482-6

M3 - Article

C2 - 31620808

AN - SCOPUS:85074045009

VL - 47

SP - 185

EP - 191

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 1

ER -